Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...

At 3 months old, Victoria Gray wouldn’t stop crying. Blood tests brought devastating news: she had sickle cell disease, a genetic blood disorder that blocks blood flow and oxygen delivery to the body.

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

The Case Western Reserve University Science and Human Rights Coalition will host Andrea Waksmunski, a PhD candidate in the Department of Genetics and Genome Sciences, for a talk titled “Ethics of ...

A group of Chinese scientists have become the first to use the game-changing gene-editing technology CRISPR-Cas9 on humans. Nature reported today that a team from Sichuan University inserted ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, ...

A quiet hope has started to grow among people living with stubborn cholesterol problems as researchers report early success with a new kind of treatment that works with only one infusion. The ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.